Research programme: alternative splicing therapeutics - Sarepta Therapeutics

Drug Profile

Research programme: alternative splicing therapeutics - Sarepta Therapeutics

Alternative Names: AVI-5038; DMD EXON 35; DMD EXON 43; DMD EXON 44; DMD EXON 50; DMD EXON 52; DMD EXON 55; DMD EXON 8; SRP 4044; SRP 4050; SRP 4052; SRP 4055; SRP 5044; SRP 5045; SRP 5050; SRP 5052; SRP 5053; SRP-4008

Latest Information Update: 01 Feb 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AVI BioPharma; Ercole Biotech
  • Developer Ercole Biotech; Murdoch University; Sarepta Therapeutics
  • Class Antisense oligonucleotides; Morpholines
  • Mechanism of Action Dystrophin expression modulators; Protein synthesis modulators; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Duchenne muscular dystrophy
  • Research Multiple sclerosis
  • Discontinued Thalassaemia

Most Recent Events

  • 01 Feb 2018 Preclinical development is ongoing in Duchenne muscular dystrophy in USA (Sarepta Therapeutics pipeline, February 2018)
  • 28 Nov 2017 No recent reports of development identified for preclinical development in Duchenne muscular dystrophy in USA (Parenteral)
  • 07 Nov 2017 Sarepta Therapeutics plans a clinical efficacy trial for Duchenne muscular dystrophy in USA in mid-2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top